Oral Transmucosal Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Oral Transmucosal Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Oral Transmucosal Drugs Market studied is expected to grow with an estimated CAGR of 7.4% over the forecast period.

COVID-19 pandemic had a short-term negative impact on the oral transmucosal drugs market owing to supply chain disruption, government-imposed lockdown, unavailability of the workforce, and restrictions on manufacturing activities. However, oral transmucosal drug manufacturers are capitalizing on the ability to offer reduced first-pass metabolism with rapid onset of action in coronavirus outbreak. These abilities make oral transmucosal drugs suitable for use in end-of-life care and palliative to offers fast relief of symptoms. It was crucial in the COVID-19 pandemic since the health of some patients tends to deteriorate rapidly in certain cases. According to a study published by the National Center for Biotechnology Information in 2020, orodispersible or transmucosal drugs offer benefits such as reducing injection frequency and inherent delays in medication administration in the community setting during the COVID-19 pandemic.

The rise in R&D activities and product launches and increase in the prevalence of targeted diseases are likely to drive the market growth over the forecast period. For instance, in June 2021, Shilpa Medicare Ltd. launched Molshil, a pediatric dose Paracetamol Oral Thin Film in India. The company received approval after complying with bioequivalence requirements. Additionally, according to the World Health Organization, in 2021, approximately 275 million people used drugs at least once in 2019. Among them, approximately 62 million people used opioids. Also, about 0.5 million people died due to drug use, and more than 70% of these deaths were associated with opioids. This is expected to increase the demand for oral transmucosal drugs for the treatment of opoid dependence in the industry.

Furthermore, the rising burden of Parkinson’s disease and migraine is likely to propel the growth of the oral transmucosal drugs market over the forecast period. For instance, according to a study published by the International Parkinson and Movement Disorder Society in 2020, “Estimation of the 2020 Global Population of Parkinson’s Disease (PD)”, an estimated 9.4 million people were living with Parkinson’s disease in 2020, higher than the previously reported 6 million cases in 2016. According to the report, approximately 930,000, 344,000, and 266,000 people affected by Parkinson’s disease in United States, Japan, and Germany in 2020, respectively.

Oral transmucosal tablets easily dissolve in the mouth with little or no residue. As the oral transmucosal tablets absorb quickly, they play a critical role during medical emergencies such as heart attacks. The tablets segment is anticipated to dominate the global market in 2020, owing to the advantages offered by oral transmucosal tablets, such as quick absorption, predictable potency, ease of administration, and reduced interaction with other medications.

Furthermore, the rise in oral transmucosal tablet approvals is expected to drive the segment growth over the forecast period. For instance, in May 2021, Breckenridge Pharmaceutical, Inc. received final approval of its Abbreviated New Drug Application from United States Food and Drug Administration for Asenapine (5mg) Sublingual Tablets. The product was developed by Breckenridge Pharmaceutical, Inc. and MSN Laboratories Private Limited. Also, in June 2018, Torii Pharmaceutical Co., Ltd launched CEDARCURE, a Japanese Cedar Pollen Sublingual Tablets. It is the sublingual immunotherapy drug for Japanese Cedar Pollen.

North America holds the major market share in the oral transmucosal drugs market and is expected to dominate the overall market, throughout the forecast period owing to the high prevalence of dysphagia, increase in the geriatric population, and the high acceptance of novel oral transmucosal drugs in the region. According to a study published by Clinical Gastroenterology and Hepatology in 2020, “Prevalence and Characteristics of Dysphagia Based on a Population-Based Survey”, dysphagia is very common in United States and affects about 16.1% of Americans at some point during their lives. In the North America region, United States is slated to be the largest market due to the presence of many oral transmucosal drug manufacturers and suppliers. In addition, according to United States Census Bureau, about 54.1 million Americans were 65 years and older in July 2019. The above-mentioned data points indicate that the prevalence of dysphagia and demand for the oral transmucosal drug is high in North America, which may drive the market over the forecast period.

The oral transmucosal drugs market is moderately competitive in nature with several players across the globe. Companies, like ZIM Laboratories Limited, Aquestive Therapeutics, Inc., IntelGenx Corp., Novartis AG, C.L.Pharm Co., Ltd., Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc., Pfizer Inc., and GW Pharmaceuticals plc. among others, hold the substantial market share in the market studied.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support